

World Journal of *Clinical Cases*

World J Clin Cases 2023 September 26; 11(27): 6318-6669



MINIREVIEWS

- 6318 Characteristics of amino acid metabolism in colorectal cancer

Xu F, Jiang HL, Feng WW, Fu C, Zhou JC

ORIGINAL ARTICLE**Clinical and Translational Research**

- 6327 Exploring the pharmacological mechanism of Wuzhuyu decoction on hepatocellular carcinoma using network pharmacology

Ouyang JY, Lin WJ, Dong JM, Yang Y, Yang HK, Zhou ZL, Wang RQ

- 6344 Identification of potential diagnostic and prognostic biomarkers for breast cancer based on gene expression omnibus

Zhang X, Mi ZH

Retrospective Cohort Study

- 6363 Treatment of proximal humeral fractures accompanied by medial calcar fractures using fibular autografts: A retrospective, comparative cohort study

Liu N, Wang BG, Zhang LF

Retrospective Study

- 6374 Effectiveness of out-fracture of the inferior turbinate with reduction nasal bone fracture

Kim SY, Nam HJ, Byeon JY, Choi HJ

- 6383 Prognostic model of hepatocellular carcinoma based on cancer grade

Zhang GX, Ding XS, Wang YL

- 6398 Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy

Choi HJ, Lee JH, Jung CS, Ryu JM, Chae BJ, Lee SK, Yu JH, Kim SW, Nam SJ, Lee JE, Jung YJ, Kim HY

- 6407 Correlation analysis of serum thyroglobulin, thyroid-stimulating hormone levels, and thyroid-cancer risk in thyroid nodule surgery

Shuai JH, Leng ZF, Wang P, Ji YC

- 6415 Closed thoracic drainage in elderly patients with chronic obstructive pulmonary disease complicated with spontaneous pneumothorax: A retrospective study

Wang W, Zhu DN, Shao SS, Bao J

Observational Study

- 6424 *Helicobacter pylori* eradication treatment for primary gastric diffuse large B-cell lymphoma: A single-center analysis

Saito M, Mori A, Kajikawa S, Yokoyama E, Kanaya M, Izumiyama K, Morioka M, Kondo T, Tanei ZI, Shimizu A

Prospective Study

- 6431** Effect of polyene phosphatidylcholine/ursodeoxycholic acid/ademetionine on pregnancy outcomes in intrahepatic cholestasis
Dong XR, Chen QQ, Xue ML, Wang L, Wu Q, Luo TF

SYSTEMATIC REVIEWS

- 6440** Maternal diaphragmatic hernia in pregnancy: A systematic review with a treatment algorithm
Augustin G, Kovač D, Karadjole VS, Zajec V, Herman M, Hrbač P

META-ANALYSIS

- 6455** Laparoscopic *vs* open radical resection in management of gallbladder carcinoma: A systematic review and meta-analysis
He S, Yu TN, Cao JS, Zhou XY, Chen ZH, Jiang WB, Cai LX, Liang X

CASE REPORT

- 6476** Acute acquired concomitant esotropia with congenital paralytic strabismus: A case report
Zhang MD, Liu XY, Sun K, Qi SN, Xu CL
- 6483** Tumor recurrence after pathological complete response in locally advanced gastric cancer after neoadjuvant therapy: Two case reports
Xing Y, Zhang ZL, Ding ZY, Song WL, Li T
- 6491** Acute peritonitis secondary to post-traumatic appendicitis: A case report and literature review
Habachi G, Aziza B, Ben-Ammar S, Maherzi O, Houas Y, Kerkeni Y, Sahli S, Jouini R
- 6498** Fournier's gangrene after insertion of thermo-expandable prostatic stent for benign prostatic hyperplasia: A case report
Jung HC, Kim YU
- 6505** Methyl-CpG-Binding protein 2 duplication syndrome in a Chinese patient: A case report and review of the literature
Xing XH, Takam R, Bao XY, Ba-alwi NA, Ji H
- 6515** Blood purification for treatment of non-liquefied multiple liver abscesses and improvement of T-cell function: A case report
Tang ZQ, Zhao DP, Dong AJ, Li HB
- 6523** Eosinophilic granulomatosis with polyangiitis, asthma as the first symptom, and subsequent Loeffler endocarditis: A case report
He JL, Liu XY, Zhang Y, Niu L, Li XL, Xie XY, Kang YT, Yang LQ, Cai ZY, Long H, Ye GF, Zou JX
- 6531** Left atrium veno-arterial extra corporeal membrane oxygenation as temporary mechanical support for cardiogenic shock: A case report
Lamastra R, Abbott DM, Degani A, Pellegrini C, Veronesi R, Pelenghi S, Dezza C, Gazzaniga G, Belliato M

- 6537** Successful treatment of eyebrow intradermal nevi by shearing combined with electrocautery and curettage: Two case reports
Liu C, Liang JL, Yu JL, Hu Q, Li CX
- 6543** Amniotic membrane mesenchymal stromal cell-derived secretome in the treatment of acute ischemic stroke: A case report
Lin FH, Yang YX, Wang YJ, Subbiah SK, Wu XY
- 6551** Managing spindle cell sarcoma with surgery and high-intensity focused ultrasound: A case report
Zhu YQ, Zhao GC, Zheng CX, Yuan L, Yuan GB
- 6558** Triplet regimen as a novel modality for advanced unresectable hepatocellular carcinoma: A case report and review of literature
Zhao Y, He GS, Li G
- 6565** Acute diquat poisoning case with multiorgan failure and a literature review: A case report
Fan CY, Zhang CG, Zhang PS, Chen Y, He JQ, Yin H, Gong XJ
- 6573** Fungal corneal ulcer after repair of an overhanging filtering bleb: A case report
Zhao J, Xu HT, Yin Y, Li YX, Zheng YJ
- 6579** Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
Chen SC, Ma DH, Zhong JJ
- 6587** Removal of a pulmonary artery foreign body during pulse ablation in a patient with atrial fibrillation: A case report
Yan R, Lei XY, Li J, Jia LL, Wang HX
- 6592** Delayed-onset *micrococcus luteus*-induced postoperative endophthalmitis several months after cataract surgery: A case report
Nam KY, Lee HW
- 6597** Anesthetic management of a pregnant patient with Eisenmenger's syndrome: A case report
Zhang Y, Wei TT, Chen G
- 6603** Recurrence of unilateral angioedema of the tongue: A case report
Matsuhisa Y, Kenzaka T, Shimizu H, Hirose H, Gotoh T
- 6613** Transverse mesocolic hernia with intestinal obstruction as a rare cause of acute abdomen in adults: A case report
Zhang C, Guo DF, Lin F, Zhan WF, Lin JY, Lv GF
- 6618** Compound heterozygous mutations in tripeptidyl peptidase 1 cause rare autosomal recessive spinocerebellar ataxia type 7: A case report
Liu RH, Wang XY, Jia YY, Wang XC, Xia M, Nie Q, Guo J, Kong QX

- 6624** Treatment of posterior interosseous nerve entrapment syndrome with ultrasound-guided hydrodissection: A case report
Qin LH, Cao W, Chen FT, Chen QB, Liu XX
- 6631** Rapidly growing extensive polypoid endometriosis after gonadotropin-releasing hormone agonist discontinuation: A case report
Zhang DY, Peng C, Huang Y, Cao JC, Zhou YF
- 6640** Preserving finger length in a patient with symmetric digital gangrene under local anesthesia: A case report
Kim KH, Ko IC, Kim H, Lim SY
- 6646** Reconstruction of the lower back wound with delayed infection after spinal surgery: A case report
Kim D, Lim S, Eo S, Yoon JS
- 6653** Solitary intraosseous neurofibroma in the mandible mimicking a cystic lesion: A case report and review of literature
Zhang Z, Hong X, Wang F, Ye X, Yao YD, Yin Y, Yang HY
- 6664** Complete response of metastatic *BRAF* V600-mutant anaplastic thyroid cancer following adjuvant dabrafenib and trametinib treatment: A case report
Lee SJ, Song SY, Kim MK, Na HG, Bae CH, Kim YD, Choi YS

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, Alexandru Corlateanu, MD, PhD, Reader (Associate Professor), Department of Respiratory Medicine, Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau 2001, Moldova. alexandru_corlateanu@yahoo.com

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJCC as 1.1; IF without journal self cites: 1.1; 5-year IF: 1.3; Journal Citation Indicator: 0.26; Ranking: 133 among 167 journals in medicine, general and internal; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Ying-Yi Yuan*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jin-Lei Wang*.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

September 26, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Tumor recurrence after pathological complete response in locally advanced gastric cancer after neoadjuvant therapy: Two case reports

Yu Xing, Zi-Li Zhang, Zhi-Ying Ding, Wei-Liang Song, Tong Li

Specialty type: Oncology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C, C
Grade D (Fair): D
Grade E (Poor): 0

P-Reviewer: Rotondo JC, Italy;
Shah OJ, India; Taheri S, Iran

Received: March 30, 2023

Peer-review started: March 30, 2023

First decision: July 3, 2023

Revised: July 8, 2023

Accepted: July 21, 2023

Article in press: July 21, 2023

Published online: September 26, 2023



Yu Xing, Zi-Li Zhang, Zhi-Ying Ding, Wei-Liang Song, Tong Li, Department of Surgery, The Third Central Clinical College of Tianjin Medical University, Tianjin 300170, China

Yu Xing, Zi-Li Zhang, Zhi-Ying Ding, Wei-Liang Song, Department of Surgery, The Third Central Hospital of Tianjin, Tianjin 300170, China

Yu Xing, Zi-Li Zhang, Zhi-Ying Ding, Wei-Liang Song, Department of Surgery, Tianjin Institute of Hepatobiliary Disease, Tianjin 300170, China

Corresponding author: Tong Li, MD, PhD, Professor, Department of Surgery, The Third Central Clinical College of Tianjin Medical University, No. 83 Jintang Road, Hedong District, Tianjin 300170, China. litong3zx@sina.com

Abstract

BACKGROUND

The pathological complete response (ypCR) rate following neoadjuvant chemotherapy for advanced gastric cancer remains low and lacks a universally accepted treatment protocol. Immunotherapy has achieved breakthrough progress.

CASE SUMMARY

We report two female patients with gastric cancer defined as clinical stage cT4N1-2M0. Detection of mismatch repair protein showed mismatch repair function defect, and perioperative treatment with programmed death protein 1 inhibitor combined with S-1+oxaliplatin achieved ypCR. Surprisingly, the patients underwent clinical observation after surgery but developed different degrees of metastasis at ~6 mo after surgery.

CONCLUSION

PD-1 inhibitor combined with chemotherapy provides a more strategic choice for comprehensive perioperative treatment of gastric cancer.

Key Words: Programmed death protein 1; SOX; Pathological complete response; Microsatellite Instability High; Mismatch repair function defect; Case report

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The enhanced antitumor effect of synergistic chemotherapy and immunotherapy has achieved commendable remission rates and survival benefit. We reported two patients who achieved pathological complete remission (ypCR) with perioperative treatment with programmed death protein 1 inhibitor combined with S-1+oxaliplatin. Surprisingly, the patients underwent clinical observation after surgery but developed different degrees of metastasis at ~6 mo after surgery. Achieving ypCR reflects an excellent short-term treatment response but does not necessarily predict long-term survival.

Citation: Xing Y, Zhang ZL, Ding ZY, Song WL, Li T. Tumor recurrence after pathological complete response in locally advanced gastric cancer after neoadjuvant therapy: Two case reports. *World J Clin Cases* 2023; 11(27): 6483-6490

URL: <https://www.wjgnet.com/2307-8960/full/v11/i27/6483.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v11.i27.6483>

INTRODUCTION

We report two female patients with gastric cancer defined as clinical stage cT4N1-2M0. The detection of mismatch repair protein showed mismatch repair function defect (dMMR), and perioperative treatment with programmed death protein 1 (PD-1) inhibitor combined with SOX (S-1+oxaliplatin) achieved pathological complete response (ypCR). It is controversial for ypCR patients to continue comprehensive chemotherapy or clinical observation after surgery. Surprisingly, both our patients underwent clinical observation after surgery but developed different degrees of metastasis at ~6 mo after surgery. This unexpected outcome prompted a review of the comprehensive perioperative treatment for these two patients in an effort to provide valuable insights for clinical decision-making.

CASE PRESENTATION

Chief complaints

Case 1: The patient was an 81-year-old woman with upper abdominal pain, loss of appetite, belching, and acid reflux for 3 mo.

Case 2: A 69-year-old female patient presented with cryptic pain in the upper abdomen and loss of appetite for 5 mo.

History of present illness

Case 1: The patient complained of upper abdominal pain without obvious inducement 3 mo previously, accompanied by loss of appetite, belching, and gastric acid reflux. Before 1 mo, the above symptoms were aggravated, and eating difficulties and nausea occurred. Since the onset of the disease, her weight has dropped by 2 kg.

Case 2: The patient had upper abdominal pain for > 5 mo, and vomiting occurred intermittently after eating. Since the onset of the disease, her body weight decreased by 4.5 kg.

History of past illness

Case 1: The patient had a history of hypertension and type 2 diabetes, and the oral medication was well-controlled.

Case 2: Previous cholecystectomy due to gallstones.

Personal and family history

Case 1: The patient had no relevant personal or family history.

Case 2: Drinking history of 40 years, no family history.

Physical examination

Case 1: Blood pressure 130/82 mmHg (normal range: 90–140/60–90 mmHg), pulse rate 72 beats/min (normal range: 60–90 beats/min), and respiratory rate 18 breaths/min (normal range: 16–20 breaths/min).

Case 2: Blood pressure 120/70 mmHg, pulse rate of 62 beats/min, and respiratory rate 17 breaths/min. Normal ranges as for Case 1.

Laboratory examinations

Case 1: Blood tests revealed abnormal results: Carbohydrate antigen (CA)19-9 378.0 U/mL (normal range: 0–39.0 U/mL); CA72-4 220 U/mL (normal range: 0–8.20 U/mL); carcinoembryonic antigen (CEA) 478.0 ng/mL (normal range: 0–5.0 ng/mL); and hemoglobin 111 g/L (normal range: 115–150 g/L).

Case 2: Blood tests revealed abnormal results: CA19-9 285.0 U/mL; CA72-4 61.5 U/mL; CEA 5.48 ng/mL; and hemoglobin 80 g/L. Normal ranges as for Case 1.

Imaging examinations

Case 1: Computed tomography (CT) was performed on the abdomen, showing gastric wall thickening in the lesser curvature of the antrum, gastric cavity stenosis with increased density of perigastric fat space, and multiple enlarged lymph nodes (Figure 1A-C). Gastroscopy showed an ulcerative mass in the antrum, and pathology showed adenocarcinoma (Figures 1D and 2A). Detection of MMR protein showed dMMR (Figure 3).

Case 2: Gastroscopy showed masses in the antrum and gastric horn, and pathology showed heterospecific cells and signet-ring cells. CT of the abdomen showed local irregular thickening of the gastric wall in the antrum and gastric horn with clumped soft tissue shadows and enlargement of multiple lymph nodes around the stomach (Figures 4A-D and 5A). MMR protein detection showed dMMR (Figure 6).

FINAL DIAGNOSIS

Case 1: According to the Eighth American Joint Committee on Cancer/Union for International Cancer Control TNM Classification of Malignant Tumors, clinical stage cT4N2M0 gastric adenocarcinoma.

Case 2: Clinical stage cT4N1M0 gastric adenocarcinoma, according to the above classification.

TREATMENT

Case 1

This patient benefited from immunosuppressive therapy. From March to May 2021, the patient, without chemotherapy contraindication, received three cycles of SOX chemotherapy (intravenous oxaliplatin 130 mg/m² on day 1, S-1 80 mg/m² after breakfast and dinner twice daily on days 1-14), plus the PD-1 inhibitor (camrelizumab) 200 mg intravenous glucose tolerance test (IVGTT) on day 1, every 3 wk. The treatment was well tolerated, and no immune-related adverse effects were observed based on tests for hematotoxicity and multiorgan function. After three cycles of treatment, abdominal CT scan on June 2, 2021 showed a significant reduction in the antral mass and perigastric lymph nodes. The efficacy of therapy was defined as partial response (PR) (Figure 1E-H). Laparoscopic comprehensive exploration and peritoneal lavage showed no metastasis and negative tumor cytology. Finally, gastric cancer D2 surgery was performed (June 2021), and the patient recovered and was discharged smoothly.

Case 2

This patient benefited from immunosuppressive therapy. From March to April 2021, she received two cycles of SOX chemotherapy in addition to PD-1 inhibitor (camrelizumab) (200 mg IVGTT on day 1, every 3 wk). The treatment was well tolerated, and no immune-related adverse effects were observed based on tests for hematotoxicity and multiorgan function. After two cycles of treatment, the patient underwent abdominal CT on April 14, 2021, which showed a decrease in the antral mass and lymph nodes around the stomach. The efficacy of treatment was defined as PR (Figure 4E-H). Laparoscopic comprehensive exploration and peritoneal lavage showed no metastasis and negative tumor cytology. Finally, gastric cancer D2 surgery was performed (May 2021), and the patient recovered and was discharged smoothly.


OUTCOME AND FOLLOW-UP

Case 1

After the D2 operation for gastric cancer, postoperative pathological examination showed the pathological stage and ypCR of ypT0N0M0 (Figure 2B). Regular follow-up was required after postoperative communication with the patient. In December 2021, liver ultrasound examination showed that two lesions in the right anterior lobe of the liver were considered metastatic, with liver biopsy indicating adenocarcinoma (Figure 2C). Radiofrequency therapy for liver tumors was performed on January 5, 2022. Because the patient refused chemotherapy after the operation, she was followed up regularly and died on May 2, 2022. The entire diagnosis and treatment schedule of the patient is shown in Figure 7A.


Case 2

After the D2 operation for gastric cancer, postoperative pathological examination showed the pathological stage and ypCR of ypT0N0M0 (Figure 5B). Because the patient insisted on continuing postoperative treatment and could not tolerate therapy after one cycle with camrelizumab 200 mg IVGTT, she requested regular follow-up. In December 2021, the patient had apparent abdominal distension caused by ascites. Tumor cell examination showed dispersed nuclear heterogeneous cells in the ascites (Figure 5C). The patient was treated with a combination of PD-1 inhibitor and S-1 for two cycles because of intraperitoneal metastasis. Because a gastrointestinal reaction occurred again, the patient did not



DOI: 10.12998/wjcc.v11.i27.6483 Copyright ©The Author(s) 2023.

Figure 1 Computed tomography and gastroscopy images before and after treatment. A–C: Computed tomography (CT) images of primary lesions before immunotherapy combined with chemotherapy; E–G: CT image of the primary lesion significantly reduced after immunotherapy combined with chemotherapy; D: Gastroscopy image before immunotherapy combined with chemotherapy; H: After immunotherapy combined with chemotherapy, the antral mass was significantly reduced by gastroscopy.




DOI: 10.12998/wjcc.v11.i27.6483 Copyright ©The Author(s) 2023.

Figure 2 Pathological section. A: Hematoxylin and eosin staining of tumor specimens before surgery; B: Postoperative pathology showed no residual tumor cells, and a complete pathological response was achieved; C: Needle biopsy of liver metastases revealed adenocarcinoma. A–C: Scale bar: 50 μ m. Magnification: 200 \times .

tolerate the treatment and was given regular follow-up observations as well as nutritional support. The last follow-up time was October 2022. The entire diagnosis and treatment schedule of the patient is shown in Figure 7B.


DISCUSSION

Gastric cancer constitutes a significant global health challenge, representing a leading cause of morbidity and mortality in the realm of gastrointestinal malignancies. As such, the standard treatment strategy for patients with a clinical assessment of T ≥ 3 , or advanced gastric cancer accompanied by lymph node metastasis, entails neoadjuvant therapy, surgery, and postoperative adjuvant therapy. However, the ypCR rate following neoadjuvant chemotherapy for advanced gastric cancer remains low and lacks a universally accepted treatment protocol[1]. Increasingly, therapeutic combinations involving checkpoint inhibitors and other antitumor agents are being proposed for various types of cancers[2–4]. Of note, recent research within the field of gastric cancer has demonstrated a growing focus on immunotherapy, with several studies underscoring the efficacy of immune checkpoint inhibitors targeting PD-1/PD-ligand 1 in patients with advanced gastric cancer[5–8]. Consequently, combining a PD-1 inhibitor with chemotherapy has demonstrated considerable benefits in terms of overall survival, progression-free survival, and tolerable safety profiles in comparison to chemotherapy alone [9]. Microsatellite instability high (MSI-H)/dMMR is a recognized marker for forecasting the effectiveness of immunotherapy in gastric cancer[10]. Additionally, the National Comprehensive Cancer Network clinical practice guidelines for gastric cancer advocate the use of PD-1 inhibitors for MSI-H/dMMR gastric cancer, which demonstrates progression post-chemotherapy[11]. Literature reveals a ypCR rate of 6% to 20% for neoadjuvant chemotherapy[12–14]. However, studies focusing on the ypCR status after neoadjuvant immunotherapy in gastric cancer are sparse. The ongoing




DOI: 10.12998/wjcc.v11.i27.6483 Copyright ©The Author(s) 2023.

Figure 3 Detection of mismatch repair protein. A: MLH1 was detected by immunohistochemistry; B: MSH2 was detected by immunohistochemistry; C: MSH6 was detected by immunohistochemistry; D: PMS2 was detected by immunohistochemistry. A–D: Scale bar: 50 μ m. Magnification: 200 \times .




DOI: 10.12998/wjcc.v11.i27.6483 Copyright ©The Author(s) 2023.

Figure 4 Computed tomography and gastroscopy images before and after treatment. A–C: Computed tomography (CT) images of primary lesions before immunotherapy combined with chemotherapy; E–G: CT image of the primary lesion significantly reduced after immunotherapy combined with chemotherapy; D: Gastroscopy image before immunotherapy combined with chemotherapy; H: After immunotherapy combined with chemotherapy, the antral mass was significantly reduced by gastroscopy.




DOI: 10.12998/wjcc.v11.i27.6483 Copyright ©The Author(s) 2023.

Figure 5 Pathological section. A: Hematoxylin and eosin staining of tumor specimens before surgery; B: Postoperative pathology showed no residual tumor cells, and a complete pathological response was achieved; C: Examination of ascites can find heterotypic cells and consider malignancy. A–C: Scale bar: 50 μ m. Magnification: 200 \times .



DOI: 10.12998/wjcc.v11.i27.6483 Copyright ©The Author(s) 2023.

Figure 6 Detection of mismatch repair protein. A: MLH1 was detected by immunohistochemistry; B: MSH2 was detected by immunohistochemistry; C: MSH6 was detected by immunohistochemistry; D: PMS2 was detected by immunohistochemistry. A–D: Scale bar: 50 μ m. Magnification: 200 \times .



DOI: 10.12998/wjcc.v11.i27.6483 Copyright ©The Author(s) 2023.

Figure 7 Timeline of diagnosis and treatment. A: Case 1; B: Case 2.

GERCOR NEONIPIGA II study is a promising development in this area and its forthcoming results are eagerly awaited [15]. Although there is little evidence for adjuvant chemotherapy in patients with ypCR after neoadjuvant therapy[16], a retrospective analysis involving 2676 patients with advanced gastric or gastroesophageal junction adenocarcinoma suggests that ypCR does not necessarily guarantee a cure. Surprisingly, ypCR patients had a high recurrence rate of 23%, including 36% developing brain metastases, compared to non-ypCR patients with a 4% incidence of brain metastases[17]. This raises questions about the effectiveness of adjuvant chemotherapy and whether there is undiscovered biological information behind ypCR. Therefore, more studies are expected to compare the choices of treatment mode after ypCR.

CONCLUSION

There is a growing body of evidence suggesting that the augmented antitumor effect resulting from the synergistic action of chemotherapy and immunotherapy leads to a commendable remission rate and survival benefit. Nevertheless, the rational and efficient amalgamation of chemotherapy and immunotherapy still presents a myriad of challenges, such as

identifying the patient cohort that would optimally benefit from immunotherapy. Achieving ypCR is an excellent short-term treatment response, but it does not necessarily predict long-term survival. The potential for a less favorable prognosis underpins the necessity for rigorous postoperative surveillance and a collaborative effort across multiple disciplines, including medicine, surgery, radiotherapy, pathology, and translational medicine. It is anticipated that advancements in translational medicine can yield a more profound understanding of molecular biological information, as well as provide a more nuanced interpretation of tumor behavior. This, in turn, could pave the way for tailored treatment strategies for such patients.

FOOTNOTES

Author contributions: Xing Y, Zhang ZL, and Ding ZY designed the research plan, compiled and analyzed the data, and drafted the manuscript; Song WL and Li T designed and supervised the research plan, analyzed the data, and completed the manuscript. All authors participated in the writing of the paper and finally approved the submitted and published version.

Supported by This work was sponsored by Tianjin Key Medical Discipline (Specialty) Construction Project, No. TJYXZDXK-035A; and Tianjin Science and Technology Project, No. 21JCYBJC01590.

Informed consent statement: Consent was obtained from the patient and her family for publication of this report.

Conflict-of-interest statement: All authors declare that there are no conflicts of interest to disclose.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Yu Xing 0000-0001-8075-9612; Zi-Li Zhang 0009-0006-3189-5160; Zhi-Ying Ding 0009-0005-8649-3778; Wei-Liang Song 0000-0002-8912-7897; Tong Li 0000-0002-1748-6030.

S-Editor: Liu JH

L-Editor: Kerr C

P-Editor: Zhao S

REFERENCES

- Kaltenmeier C, Althans A, Mascara M, Nassour I, Khan S, Hoehn R, Zureikat A, Tohme S. Pathologic Complete Response Following Neoadjuvant Therapy for Gastric Adenocarcinoma: A National Cancer Database Analysis on Incidence, Predictors, and Outcomes. *Am Surg* 2021; **87**: 1145-1154 [PMID: 33342268 DOI: 10.1177/0003134820972083]
- Li X, Su X, Liu R, Pan Y, Fang J, Cao L, Feng C, Shang Q, Chen Y, Shao C, Shi Y. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. *Oncogene* 2021; **40**: 1836-1850 [PMID: 33564072 DOI: 10.1038/s41388-020-01636-x]
- Mazziotta C, Lanzillotti C, Gafà R, Touzé A, Durand MA, Martini F, Rotondo JC. The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma. *Front Oncol* 2022; **12**: 832047 [PMID: 35350569 DOI: 10.3389/fonc.2022.832047]
- Borcoman E, Kamal M, Marret G, Dupain C, Castel-Ajgal Z, Le Tourneau C. HDAC Inhibition to Prime Immune Checkpoint Inhibitors. *Cancers (Basel)* 2021; **14** [PMID: 35008230 DOI: 10.3390/cancers14010066]
- Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. *Lancet* 2018; **392**: 123-133 [PMID: 29880231 DOI: 10.1016/S0140-6736(18)31257-1]
- Huo G, Liu W, Chen P. Efficacy of PD-1/PD-L1 inhibitors in gastric or gastro-oesophageal junction cancer based on clinical characteristics: a meta-analysis. *BMC Cancer* 2023; **23**: 143 [PMID: 36765356 DOI: 10.1186/s12885-023-10605-y]
- Brar G, Shah MA. The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma. *Therap Adv Gastroenterol* 2019; **12**: 1756284819869767 [PMID: 31516556 DOI: 10.1177/1756284819869767]
- Voutsadakis IA. A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma. *Euroasian J Hepatogastroenterol* 2020; **10**: 56-63 [PMID: 33511066 DOI: 10.5005/jp-journals-10018-1321]
- Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzian MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet* 2021; **398**:

- 27-40 [PMID: 34102137 DOI: 10.1016/S0140-6736(21)00797-2]
- 10 **Le DT**, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, Wong F, Azad NS, Rucki AA, Laheru D, Donehower R, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Greten TF, Duffy AG, Ciombor KK, Eyring AD, Lam BH, Joe A, Kang SP, Holdhoff M, Danilova L, Cope L, Meyer C, Zhou S, Goldberg RM, Armstrong DK, Bever KM, Fader AN, Taube J, Housseau F, Spetzler D, Xiao N, Pardoll DM, Papadopoulos N, Kinzler KW, Eshleman JR, Vogelstein B, Anders RA, Diaz LA Jr. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. *Science* 2017; **357**: 409-413 [PMID: 28596308 DOI: 10.1126/science.aan6733]
- 11 **Ajani JA**, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, Farjah F, Gerdes H, Gibson MK, Hochwald S, Hofstetter WL, Ilson DH, Keswani RN, Kim S, Kleinberg LR, Klempner SJ, Lacy J, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Outlaw D, Park H, Perry KA, Pimiento J, Poultides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian N, Pluchino LA. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2022; **20**: 167-192 [PMID: 35130500 DOI: 10.6004/jnccn.2022.0008]
- 12 **Thuss-Patience PC**, Hofheinz RD, Arnold D, Florschütz A, Daum S, Kretzschmar A, Mantovani-Löffler L, Bichev D, Breithaupt K, Kneba M, Schumacher G, Glanemann M, Schlattmann P, Reichardt P, Gahn B. Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. *Ann Oncol* 2012; **23**: 2827-2834 [PMID: 22734012 DOI: 10.1093/annonc/mds129]
- 13 **Schulz C**, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T, Schäfer C, Stintzing S, Giessen C, Modest DP, Ridwelski K, Heinemann V. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. *Int J Cancer* 2015; **137**: 678-685 [PMID: 25530271 DOI: 10.1002/ijc.29403]
- 14 **Al-Batran SE**, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegler W, Pohl M, Heike M, Ronellenfitsch U, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozael W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. *Lancet Oncol* 2016; **17**: 1697-1708 [PMID: 27776843 DOI: 10.1016/S1470-2045(16)30531-9]
- 15 **Cohen R**, Pudlarz T, Garcia-Larnicol ML, Vernerey D, Dray X, Clavel L, Jary M, Piessen G, Zaanen A, Aparicio T, Louvet C, Tournigand C, Chibaudel B, Tougeron D, Guimbaud R, Benouna J, Adenis A, Sokol H, Borg C, Duval A, Svrcek M, André T. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]. *Bull Cancer* 2020; **107**: 438-446 [PMID: 32057467 DOI: 10.1016/j.bulcan.2019.11.016]
- 16 **Wang T**, Wang N, Zhou H, Zhou A, Jin J, Chen Y, Zhao D. Long-term survival results of patients with locally advanced gastric cancer and pathological complete response after neoadjuvant chemotherapy and resection. *Transl Cancer Res* 2020; **9**: 529-535 [PMID: 35117397 DOI: 10.21037/tcr.2019.11.37]
- 17 **Fields RC**, Strong VE, Gönen M, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG, Shah MA. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastroesophageal adenocarcinoma. *Br J Cancer* 2011; **104**: 1840-1847 [PMID: 21610705 DOI: 10.1038/bjc.2011.175]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

